Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Role for PET (Positron emission tomography) as breast cancer theranostic:

This article was originally published in Clinica

Executive Summary

Positron emission tomography (PET) could prove useful in theranostic tests for breast cancer. So say Australian scientists based at the Monash Medical Centre in Melbourne, who have found that the technology can monitor women's response to chemotherapy, more effectively than mammography and ultrasound. According to the data, women who have a larger percentage drop in FDG-PET readings of their tumours, after receiving chemotherapy, were more likely to have a complete response to the treatment, and hence survive. FDG-PET could prove an important addition to conventional imaging of breast cancer, and may contribute significantly to more personalised disease management, claimed the researchers. They presented their results at the conference of the European CanCer Organisation (ECCO) in Barcelona, Spain, from 23-27 September.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049842

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel